众生药业(002317) - 2026年1月29日投资者关系活动记录表

Financial Performance - The company's net profit for 2025 is expected to be between RMB 260 million and RMB 310 million, representing a year-on-year growth of 186.91% to 203.62% [1] - The net profit after deducting non-recurring gains and losses is projected to be between RMB 270 million and RMB 320 million, with a growth rate of 203.72% to 222.93% [1] Strategic Partnerships - A licensing agreement was signed with Qilu Pharmaceutical on January 16, 2026, for the production and commercialization of RAY1225 injection in China, with an upfront payment of RMB 200 million [3] - The total potential milestone payments from Qilu Pharmaceutical could reach RMB 800 million, in addition to a double-digit royalty on net sales [3] Innovation and R&D Pipeline - The company focuses on innovative drug development for metabolic diseases and respiratory diseases, with two innovative drugs already approved for market [6][7] - RAY1225 injection, a dual receptor agonist, is currently undergoing multiple Phase III clinical trials for obesity and type 2 diabetes, showing promising efficacy and safety [11][12] - The company is also developing ZSP1601 tablets for metabolic dysfunction-related fatty liver disease, which has shown significant results in clinical trials [6] Market Opportunities - The market for metabolic-associated fatty liver disease (MASH) is substantial, with no approved treatments currently available, indicating a significant unmet clinical need [14] - Obstructive sleep apnea (OSA) affects approximately 176 million people in China, with RAY1225 injection potentially offering a new treatment option for this condition [16][18] Clinical Trial Progress - RAY1225 injection has completed Phase II trials with positive results, and Phase III trials are ongoing for various indications, including obesity and type 2 diabetes [12][17] - The company is committed to advancing its clinical trials with high quality and speed, focusing on innovative solutions for metabolic diseases and respiratory conditions [13]